United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2021_register
executive
2021-06-24
article
Prospective Grant of an Exclusive Patent License: Development and Commercialization of Monospecific CD22 Chimeric Antigen Receptor (CAR) Therapies for the Treatment of B-Cell Malignancies
Notices
D09002ee1bdb21c6c
D09002ee1bdb221d8
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
National Institutes of Health
originator
org
United States Government Agency or Subagency
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Syncopation Life Sciences Inc., (``Syncopation''), located in Palo Alto, California.
86 FR 33326
https://www.govinfo.gov/app/details/FR-2021-06-24/2021-13260
2021-13260
fr24jn21-156
4140-01-P
https://www.govinfo.gov/app/details/FR-2021-06-24/2021-13260
https://www.govinfo.gov/content/pkg/FR-2021-06-24/html/2021-13260.htm
https://www.govinfo.gov/content/pkg/FR-2021-06-24/pdf/2021-13260.pdf
2 p.
33326
33327
86 FR 33326
Prospective Grant of an Exclusive Patent License: Development and Commercialization of Monospecific CD22 Chimeric Antigen Receptor (CAR) Therapies for the Treatment of B-Cell Malignancies; Federal Register Vol. 86, Issue
NOTICE
2021-13260
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
2021-07-09
4140-01-P
2021-13260
Notice.
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Syncopation Life Sciences Inc., (``Syncopation''), located in Palo Alto, California.
Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before July 9, 2021 will be considered.
Prospective Grant of an Exclusive Patent License:
Development and Commercialization of Monospecific CD22 Chimeric Antigen Receptor Therapies for the Treatment of B-Cell Malignancies,
jim.knabb@nih.gov
Federal Register
Vol. 86, no. 119
Office of the Federal Register, National Archives and Records Administration
2021-06-24
continuing
daily
deposited
born digital
414 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2021-06-24
P0b002ee1aec840c4
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr24jn21
https://www.govinfo.gov/app/details/FR-2021-06-24
https://www.govinfo.gov/content/pkg/FR-2021-06-24/pdf/FR-2021-06-24.pdf
https://www.govinfo.gov/content/pkg/FR-2021-06-24/xml/FR-2021-06-24.xml
fdlp
33077
33477
DGPO
2021-06-24
2023-04-27
FR-2021-06-24
machine generated
eng
FR
FR-2021-06-24
86
119